Dow Chemical and Cambrex Complete Facility for Drug-Solubility Solutions
Dow Chemical and Cambrex open a new facility for Dow?s hydroxypropyl methylcellulose acetate succinate (HPMCAS).
Dow Chemical and Cambrex have opened a new facility for Dow’s hydroxypropyl methylcellulose acetate succinate (HPMCAS) for drug solubility enhancement at Cambrex’s site in karlskoga, Sweden. The Cambrex Karlskoga expansion began in early 2013.
The facility completion and start of the HPMCAS product validation is part of the solubilization partnership between Dow and Bend Research, announced in October 2012. Beginning in 2014, Dow will be able to commercially supply solubility enabling excipients.
Source: Dow Chemical
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
